In the Headlines- How Tufts Is Convening a Call for a National Nutrition Research ‘Moonshot’
This was a recent great post that should have been published now as many are heading back to work. It highlights how we really need a change in how we conduct and fund nutrition research from top experts in the field.
The objective of this review was to “examine emerging evidence of the influence of obesity on COVID‐19, the challenges to clinical management from pulmonary, endocrine and immune dysfunctions in individuals with obesity and identify potential areas for further research”. The conclusions of this review are “that people with severe obesity be deemed a vulnerable group for COVID‐19 and the clinical trials of pharmacotherapeutics, immunotherapies and vaccination should prioritize the inclusion of people with obesity”.
The association of the ACTN3 R577X and ACE I/D polymorphisms with athlete status in football: a systematic review and meta-analysis
This review aimed “to assess the association of ACTN3 R577X and ACE I/D polymorphisms with athlete status in football and determine which allele and/or genotypes are most likely to influence this phenotype via a meta-analysis”. The results suggest that “significant associations were shown between the presence of the ACTN3 R allele and professional footballer status (OR = 1.35, 95% CI: 1.18–1.53) and the ACE D allele and youth footballers (OR = 1.18, 95% CI: 1.01–1.38). More specifically, the ACTN3 RR genotype (OR = 1.48, 95% CI: 1.23–1.77) and ACE DD genotype (OR = 1.29, 95% CI: 1.02–1.63) exhibited the strongest associations, respectively. These findings may be explained by the association of the ACTN3 RR genotype and ACE DD genotype with power-orientated phenotypes and the relative contribution of power-orientated phenotypes to success in football. The results of this review provide further evidence that individual genetic variation may contribute to athlete status. It can differentiate athletes’ competitive playing statuses in a homogenous team-sport cohort. Moreover, the ACTN3 R577X and ACE I/D polymorphisms are likely (albeit relatively minor) contributing factors that influence athlete status in football”
This cross-sectional study was done in a sample of 123 parents “aimed to identify the proportion of overweight that can be explained by known parental risk factors, including genetic, lifestyle, and social determinants of health with offspring weight status in the UK.” The “parental genetic data was collected by using GeneFiX saliva collection vials and genotypes were assessed for brain-derived neurotrophic factor (BDNF) gene rs6265, melanocortin 4 receptor (MC4R) gene rs17782313, transmembrane protein 18 (TMEM18) gene rs2867125, and serine/threonine-protein kinase (TNN13K) gene rs1514175”. The results suggest that, “maternal body mass index modestly predicted child weight status (p < 0.015; R2 = 0.15). More mothers of overweight children carried the MC4R rs17782313 risk allele (77.8%; p = 0.007) compared to mothers of normal-weight children. Additionally, fathers who were not Caucasian and parents who slept for <7 h/night had a larger percentage of overweight children when compared to their counterparts (p = 0.039; p = 0.014, respectively)”.
Change in Weight, BMI, and Body Composition in a Population‐Based Intervention Versus Genetic‐Based Intervention: The NOW Trial
The Nutrigenomics, Overweight/Obesity, and Weight Management (NOW) trial is a parallel‐group, pragmatic, randomized controlled clinical trial incorporated into the Group Lifestyle BalanceTM (GLB) Program. This study aimed to “compare changes in body fat percentage (BFP), weight, and BMI between a standard intervention (12‐month GLB program) and a nutrigenomics intervention (modified 12‐month program (GLB plus nutrigenomics)”. The comparison between the two methods had the primary outcome of percent change in BFP and a secondary outcome of change in the weight and in the BMI. The results showed that “the GLB plus nutrigenomics group experienced significantly (P < 0.05) greater reductions in percent and absolute BFP at the 3‐month follow‐up and percent BFP at the 6‐month follow‐up compared with the standard GLB group”. In conclusion “the nutrigenomics intervention used in the NOW trial can optimize changes in body composition up to 6 months”.
This review discusses ”how genetic information combined with longitudinal metabolomic, immune, behavioral, and gut microbial parameters, and bioclinical variables could define a digital replica of oneself, a “virtual digital twin,” which could serve to guide nutrition in a personalized manner. Such a model may revolutionize the management of obesity and its comorbidities, and provide a pillar for healthy aging”.
“This review aims to briefly summarize the role of the most important genes associated with obesity and CVD and to clarify the knowledge about the relation between nutrition and gene expression and the role of the main nutrition-related genes in obesity and CVD. (…)There is a marked variation in CVD in patients with obesity and the same dietary pattern. The different genetic polymorphisms could explain this variation, which leads to the emergence of the concept of nutrigenetics. (…) Thus, the personalized nutrition recommendations, based on the knowledge of an individual’s genetic background, might improve the outcomes of a specific dietary intervention and represent a new dietary approach to improve health, reducing obesity and CVD. Given these premises, it is intuitive to suppose that the elucidation of diet and gene interactions could support more specific and effective dietary interventions in both obesity and CVD prevention through personalized nutrition based on nutrigenetics”.
Bayer has taken a further stake in New York-based One Drop to support its plans to become a digital health business by developing new integrated care services for patients.
2) Digital enthusiast (9%): “These consumers value and prioritize all things technology. They likely use online platforms for everyday tasks and are interested in keeping up with the latest technological trends. They are also unlikely to invest in their personal image or the latest trends unless they are related to technology.”